Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2025 16:01 ET | Source: Genelux Corporation

Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference

WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
August 07, 2025 16:20 ET | Source: Genelux Corporation

Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
July 07, 2025 07:00 ET | Source: Genelux Corporation

Genelux Corporation Announces Appointment of Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

WESTLAKE VILLAGE, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Eric Groen as...
May 06, 2025 16:10 ET | Source: Genelux Corporation

Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates

WESTLAKE VILLAGE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter...
May 01, 2025 16:05 ET | Source: Genelux Corporation

Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and...
March 28, 2025 16:10 ET | Source: Genelux Corporation

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2...
March 25, 2025 08:31 ET | Source: Genelux Corporation

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an...
March 25, 2025 08:30 ET | Source: Genelux Corporation

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March ...
March 25, 2025 08:30 ET | Source: Genelux Corporation

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

– Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a...
February 03, 2025 06:45 ET | Source: Genelux Corporation

Genelux Corporation Announces New Chief Financial Officer

WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the...